In particular, the combined treatment effectively inhibited HSPB1 expression, increased levels of TFRC (transferrin receptor), COX2 (cyclooxygenase 2), Fe2+, and ROS, together with a decrease in glutathione (GSH) levels, suggesting this strategy as a reliable one to overcome sorafenib resistance in HCC. The gene discussed is PTGS2; the disease is hepatocellular carcinoma.